Literature DB >> 16831861

A rapid functional assay for the human trace amine-associated receptor 1 based on the mobilization of internal calcium.

Hernán A Navarro1, Brian P Gilmour, Anita H Lewin.   

Abstract

The molecular targets for trace amines (TAs) such as p-tyramine and beta-phenylethylamine have been recently discovered and have been shown to comprise a family of G-protein-coupled receptors based on DNA sequence homologies. These have been termed trace amine-associated receptors (TAARs) because TAs do not activate all of the identified receptors. Because TA may be involved in modulating a variety of behaviors including mood, cognition, and addiction, it is of interest to discover novel ligands for TAARs to probe the role TAs play in brain function. Pharmacophore development for the G(s)-coupled human TAAR1 (hTAAR1) would be aided by a rapid functional assay amenable to screening libraries of compounds. Accordingly, the authors used RD-HGA16 CHO-1 cells from Molecular Devices, which stably express the promiscuous G(q), G(alpha16), to create a cell line stably expressing hTAAR1, thereby coupling receptor activation to the mobilization of internal calcium. They used this cell line to develop a homogenous fluorometric imaging plate reader-based assay using the Calcium 3 fluorescent dye. The EC50 and Emax data obtained for known TAs are in close agreement with previous work using transient hTAAR1 expression systems or a chimeric receptor. These data indicate that the hTAAR1 retains its reported pharmacological characteristics when coupled to G(alpha16).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831861     DOI: 10.1177/1087057106289891

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  12 in total

1.  Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).

Authors:  Gregory M Miller
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

2.  Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.

Authors:  Anita H Lewin; Gregory M Miller; Brian Gilmour
Journal:  Bioorg Med Chem       Date:  2011-10-13       Impact factor: 3.641

3.  TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-383856.

Authors:  Marcus Saarinen; Ioannis Mantas; Ivana Flais; Richard Ågren; Kristoffer Sahlholm; Mark J Millan; Per Svenningsson
Journal:  Neuropsychopharmacology       Date:  2022-09-13       Impact factor: 8.294

Review 4.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

Review 5.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

Review 6.  International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature.

Authors:  Janet J Maguire; William A E Parker; Steven M Foord; Tom I Bonner; Richard R Neubig; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

7.  Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.

Authors:  Anita H Lewin; Hernán A Navarro; S Wayne Mascarella
Journal:  Bioorg Med Chem       Date:  2008-06-13       Impact factor: 3.641

8.  Amiodarone and its putative metabolites fail to activate wild type hTAAR1.

Authors:  Anita H Lewin; Hernán A Navarro; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2009-08-20       Impact factor: 2.823

9.  Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites.

Authors:  Aaron N Snead; Motonori Miyakawa; Edwin S Tan; Thomas S Scanlan
Journal:  Bioorg Med Chem Lett       Date:  2008-08-09       Impact factor: 2.823

10.  Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.

Authors:  Yoshitsugu Nakamura; Shigeki Arawaka; Hiroyasu Sato; Asuka Sasaki; Taro Shigekiyo; Kazue Takahata; Hiroko Tsunekawa; Takeo Kato
Journal:  J Neurosci       Date:  2021-07-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.